Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Clin Cancer Res. 2015 Oct 7;22(3):734–745. doi: 10.1158/1078-0432.CCR-15-0143

Table 1.

Cox Proportional Hazard Regression models for survival on PETACC3 dataset.

a. Univariate models for overall survival (OS), relapse free survival (RFS) and/or survival after relapse (SAR) by ΔPC1.EMT score on PETACC3 Stage II&III and Stage III patients
Covariates HR (95% CI) p n
OS for Stage II and III 1.56 (1.32–1.84) 1.16e-07 752

OS for Stage III 1.69 (1.42–2.03) 8.22e-09 644

RFS for Stage II and III 1.47 (1.28–1.69) 8.98e-08 752

RFS for Stage III 1.55 (1.33–1.81) 3.99e-08 644

SAR for Stage II and III 1.20 (1.02–1.42) 3.11e-02 291

SAR for Stage III 1.26 (1.04–1.51) 1.54e-02 241
b. Univariate models for OS by ΔPC1.EMT, PC1 and EMT scores as well as other clinic-pathological and molecular variables on PETACC3 Stage III patients (n=644)
Covariates HR (95% CI) p
ΔPC1.EMT 1.69 (1.42–2.03) 8.22e-09
PC1 1.41 (1.20–1.67) 5.13e-05
EMT 1.28 (1.07–1.53) 8.21e-03
MSI (MSS vs. MSI-H) 1.49 (0.81–2.75) 2.00e-01
BRAF (wt vs. mut) 0.57 (0.34–0.95) 3.04e-02
site (right vs. left) 1.42 (1.06–1.91) 1.84e-02
T stage (T1,2 vs. T3) 0.36 (0.16–0.82) 1.47e-02
T stage (T4 vs. T3) 2.03 (1.45–2.86) 4.09e-05
grade (G-3,4 vs. G-1,2) 1.89 (1.26–2.82) 2.07e-03
SMAD4 (Any Loss vs. No Loss) (45) 1.57 (1.13–2.16) 6.75e-03
KRAS (mut vs. wt) 1.49 (1.10–2.01) 9.93e-03
BRAF.score (23) 1.34 (1.20–1.50) 1.84e-07
Age 1.09 (0.94–1.25) 2.49e-01
LN (No. of lymph nodes) 0.81 (0.68–0.97) 1.95e-02
c. Multivariate models for OS including PC1 and EMT scores as well as other clinic-pathological and molecular variables on PETACC3_Stage III patients (n=644)
Covariates HR (95% CI) p
PC1 3.22 (1.82–5.7) 5.62e-005
EMT 0.37 (0.2–0.67) 1.14e-003
Age 1.08 (0.93–1.25) 3.14e-001
T stage (T1,2 vs T3) 0.48 (0.21–1.11) 8.65e-002
T stage (T4 vs T3) 1.96 (1.39–2.77) 1.32e-004
N stage (N2 vs N1) 2.11 (1.57–2.85) 9.50e-007
LN (No. of lymph nodes) 0.73 (0.6–0.88) 9.13e-004
site (right vs left) 1.75 (1.27–2.4) 5.75e-004
MSI (MSS vs MSI-H) 1.92 (1–3.67) 4.96e-002
BRAF (wt vs mut) 0.87 (0.5–1.52) 6.34e-001
d. Multivariate models for OS including ΔPC1.EMT or PC1or EMT scores as well as other clinic-pathological and molecular variables on PETACC3_Stage III patients (n=644)
ΔPC1.EMT PC1 EMT
Covariates HR (95% CI) p HR (95% CI) p HR (95% CI) p
Scores 1.50 (1.25–1.81) 1.61e-05 1.32 (1.11–1.58) 2.12e-03 1.21 (1.00–1.46) 4.97e-02
Age 1.04 (0.89–1.20) 6.37e-01 1.04 (0.90–1.21) 5.95e-01 1.03 (0.89–1.20) 6.64e-01
Tstage (T12 vs T3) 0.51 (0.22–1.16) 1.09e-01 0.51 (0.22–1.19) 1.20e-01 0.48 (0.21–1.11) 8.50e-02
Tstage (T4 vs T3) 2.07 (1.46–2.92) 3.92e-05 2.09 (1.48–2.96) 3.03e-05 2.12 (1.50–3.00) 2.36e-05
Nstage (N2 vs N1) 2.18 (1.61–2.94) 3.87e-07 2.23 (1.65–3.00) 1.46e-07 2.25 (1.67–3.03) 9.43e-08
LN 0.73 (0.60–0.88) 8.57e-04 0.73 (0.61–0.88) 1.03e-03 0.73 (0.61–0.88) 1.01e-03
Site (right vs left) 1.70 (1.24–2.34) 1.03e-03 1.61 (1.17–2.21) 3.51e-03 1.60 (1.16–2.20) 3.86e-03
MSI (MSS vs MSI-H) 1.90 (0.99–3.65) 5.22e-02 2.19 (1.14–4.21) 1.80e-02 2.22 (1.15–4.27) 1.69e-02
BRAF (mut vs wt) 1.48 (0.82–2.65) 1.93e-01 1.75 (0.98–3.11) 5.65e-02 1.83 (1.03–3.26) 3.86e-02
KRAS (mut vs wt) 1.59 (1.14–2.21) 5.73e-03 1.64 (1.18–2.28) 3.32e-03 1.64 (1.18–2.28) 3.54e-03

Note: the scores were standardized by IQR.